Literature DB >> 8334840

A placebo-controlled double-blind study of epalrestat (ONO-2235) in patients with diabetic neuropathy.

Y Goto1, N Hotta, Y Shigeta, N Sakamoto, S Kito, K Matsuoka, A Takahashi, R Kikkawa, A Sakuma.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8334840     DOI： 10.1111/j.1464-5491.1993.tb00197.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN： 0742-3071            Impact factor:   4.359


× No keyword cloud information.
  3 in total

Review 1.  The efficacy of aldose reductase inhibitors in the management of diabetic complications. Comparison with intensive insulin treatment and pancreatic transplantation.

Authors:  J M van Gerven; A M Tjon-A-Tsien
Journal:  Drugs Aging       Date:  1995-01       Impact factor: 3.923

Review 2.  Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus.

Authors:  J W Steele; D Faulds; K L Goa
Journal:  Drugs Aging       Date:  1993 Nov-Dec       Impact factor: 3.923

3.  Efficacy, safety, and tolerability of Epalrestat compared to Methylcobalamine in patients with diabetic neuropathy.

Authors:  Manish Maladkar; Girish Rajadhyaksha; N Venkataswamy; R S Hariharan; Sathis R Lohati
Journal:  Int J Diabetes Dev Ctries       Date:  2009-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.